Skip to main content
Pharma Equity Group A/S logo

Pharma Equity Group A/S — Investor Relations & Filings

Ticker · BLVIS ISIN · DK0061155009 LEI · 2138008SUI4D917FKN20 CO Financial and insurance activities
Open in API
Filings indexed 1,627 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country DK Denmark
Listing CO BLVIS

About Pharma Equity Group A/S

https://bcbsfepvision.com/

Pharma Equity Group A/S is an investment company specializing in early-stage biotechnology, life science, and MedTech companies. The group's mission is to support its portfolio companies in developing novel therapies and effective medicines for unmet medical needs. A primary investment is its subsidiary, Reponex Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious, acute, and chronic inflammatory diseases. The company is actively expanding its portfolio through strategic acquisitions to support its growth.

Recent filings

Filing Released Lang Actions
Pharma Equity Group’s subsidiary Reponex takes key step forward in Inflammatory Bowel Disease with upcoming European patent grant
Regulatory Filings Classification · 87% confidence The document is a short (≈4,400 character) press release announcing that Pharma Equity Group’s subsidiary received notice of intention to grant a European patent. It does not contain financial statements, no detailed report or presentation, nor is it certifying or publishing a formal report. It is a regulatory announcement of a material event with no specific category for patents, so it falls into the fallback category “Regulatory Filings (RNS).”
2026-05-11 Danish
Pharma Equity Group’s subsidiary Reponex takes key step forward in Inflammatory Bowel Disease with upcoming European patent grant
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing that the company’s subsidiary has received notice of a forthcoming European patent approval. It is not a financial report (annual, interim, or audit), nor an earnings release, board change, dividend notice, share transaction, M&A announcement, or other defined category. It is a general regulatory/announcement update about patent progress and thus falls under the fallback category “Regulatory Filings (RNS).”
2026-05-11 Danish
Pharma Equity Group’s subsidiary Reponex takes key step forward in Inflammatory Bowel Disease with upcoming European patent grant
Regulatory Filings Classification · 70% confidence The document is a corporate press release announcing a patent milestone (intended grant of a European patent) by the company’s subsidiary. It does not present financial statements, voting results, or management changes, nor is it a formal annual or interim report. It is not reporting a share transaction, dividend, or a regulatory call transcript. Therefore, it falls under the fallback category for general regulatory announcements.
2026-05-11 English
Pharma Equity Group’s subsidiary Reponex takes key step forward in Inflammatory Bowel Disease with upcoming European patent grant
Regulatory Filings Classification · 75% confidence The document is a corporate announcement about a European patent grant for a subsidiary’s pharmaceutical program. It does not include financial statements, voting results, management changes, dividends, capital structure updates, or other specific regulatory filings categories. This is a general regulatory announcement and falls under the fallback “Regulatory Filings” category.
2026-05-11 English
Pharma Equity Group A/S - Annual Report 2025
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2025' for Pharma Equity Group A/S and contains detailed sections typical of an annual report, including CEO and Chairman letters, company information, principal activities, financial review, outlook, corporate governance, risk management, shareholder information, management, auditor's report, consolidated financial statements, and notes. The document covers the full fiscal year ended 31 December 2025 and includes comprehensive financial data and analysis. The length of the document (15,000 characters) and the presence of substantive financial statements confirm it is the full annual report, not just an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K).
2026-03-25 Danish
Pharma Equity Group A/S - Annual Report 2025
Report Publication Announcement Classification · 95% confidence The document is an announcement from Pharma Equity Group A/S regarding their 2025 Annual Report ('Årsrapport 2025'). It provides a summary of key financial highlights, operational updates, and future outlooks. While it contains substantive financial data (tables and performance metrics), it is structured as a press release/announcement (Announcement no. 3) rather than the full, audited annual report document itself. According to the 'Menu vs Meal' rule, this is a summary announcement of the report, which falls under the Report Publication Announcement (RPA) category. FY 2025
2026-03-25 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.